Core Insights - The article highlights the challenges faced by grassroots medical institutions in China due to a surge in respiratory infectious diseases, particularly influenza, amid a strong cold wave [1][2] - The digital pharmaceutical platform, Yaoshi Bang, is actively addressing the medication supply needs at the grassroots level through its digital supply chain system [1] Group 1: Company Performance - Yaoshi Bang has established deep strategic partnerships with several domestic pharmaceutical companies to ensure stable supply of core medications, including a full range of influenza treatment drugs like Oseltamivir [1] - The platform has reported a 36% year-on-year increase in overall sales of influenza-related medications since October 2025, with demand for Oseltamivir granules and capsules surging by 120% [1] - The company's proprietary brand "Leyaoshi" for cold medications has also seen a sales increase of over 135% year-on-year due to its cost-effectiveness [1] Group 2: Industry Context - The National Influenza Center's latest monitoring indicates an upward trend in influenza activity in southern provinces of China, with a notable increase in the positive rate of H3N2 influenza virus tests in certain areas [1] - The combination of high influenza incidence and cold weather has intensified the need for timely replenishment and precise allocation of grassroots medical resources, which is critical for effective disease control [2] - Yaoshi Bang's integration of upstream pharmaceutical resources, intelligent scheduling, and downstream rapid testing services enhances its capability to provide comprehensive support for medication supply and diagnosis during the flu season [2]

Core Insights - The article highlights the challenges faced by grassroots medical institutions in China due to a strong cold wave and a surge in respiratory infectious diseases, particularly influenza [1][2] - The digital pharmaceutical platform, Yaoshi Bang, is actively addressing the medication supply and treatment service demands in grassroots healthcare through its digital supply chain system [1] Group 1: Company Performance - Yaoshi Bang has established deep strategic partnerships with several domestic pharmaceutical companies to ensure stable supply of core medications, including a full range of influenza treatment drugs like Oseltamivir [1] - The platform reported a significant increase in sales of influenza-related medications, with an overall sales growth of 36% year-on-year since October 2025, and a 120% increase in sales of Oseltamivir products [1] - The company's own brand, "Leyaoshi," saw a sales growth exceeding 135% year-on-year due to its cost-effective offerings [1] Group 2: Service Innovations - Yaoshi Bang has introduced the "Spectrum Cabin" smart healthcare solution to empower the diagnostic end, alleviating pressure on grassroots healthcare during the flu season [2] - The core product, the Immunity Small Box, supports rapid testing for influenza A and B, with a month-on-month increase in testing numbers exceeding 60% in October [2] - The integration of upstream pharmaceutical resources, intelligent scheduling, and downstream smart testing services enhances Yaoshi Bang's ability to provide comprehensive support for medication supply and treatment during the flu season [2]